Simplex Trading’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $771K | Buy |
+45,550
| New | +$638K | ﹤0.01% | 3076 |
|
|
2025
Q4 | – | Sell |
-147,300
| Closed | -$2.03M | – | 9591 |
|
|
2025
Q3 | $2.54M | Buy |
147,300
+70,523
| +92% | +$869K | ﹤0.01% | 2085 |
|
|
2025
Q2 | $720K | Sell |
76,777
-64,490
| -46% | -$530K | ﹤0.01% | 3135 |
|
|
2025
Q1 | $1M | Buy |
141,267
+30,736
| +28% | +$310K | ﹤0.01% | 2706 |
|
|
2024
Q4 | $1.29M | Buy |
110,531
+31,537
| +40% | +$492K | ﹤0.01% | 2603 |
|
|
2024
Q3 | $1.62M | Buy |
78,994
+38,206
| +94% | +$881K | ﹤0.01% | 2458 |
|
|
2024
Q2 | $912K | Sell |
40,788
-23,885
| -37% | -$569K | ﹤0.01% | 3016 |
|
|
2024
Q1 | $1.78M | Buy |
64,673
+52,922
| +450% | +$1.47M | ﹤0.01% | 2524 |
|
|
2023
Q4 | $358K | Buy |
+11,751
| New | +$338K | ﹤0.01% | 4041 |
|
|
2023
Q3 | – | Sell |
-36,386
| Closed | -$1.41M | – | 9467 |
|
|
2023
Q2 | $1.48M | Buy |
36,386
+30,490
| +517% | +$1.24M | ﹤0.01% | 2222 |
|
|
2023
Q1 | $219K | Buy |
5,896
+4,047
| +219% | +$159K | ﹤0.01% | 4217 |
|
|
2022
Q4 | $64K | Sell |
1,849
-195
| -10% | -$9.27K | ﹤0.01% | 5568 |
|
|
2022
Q3 | $114K | Buy |
+2,044
| New | +$127K | ﹤0.01% | 5340 |
|
|
2022
Q2 | – | Sell |
-860
| Closed | -$43.7K | – | 10719 |
|
|
2022
Q1 | $62K | Sell |
860
-1,483
| -63% | -$126K | ﹤0.01% | 6837 |
|
|
2021
Q4 | $277K | Sell |
2,343
-5,492
| -70% | -$688K | ﹤0.01% | 4691 |
|
|
2021
Q3 | $1.34M | Buy |
7,835
+7,348
| +1,509% | +$1.11M | ﹤0.01% | 2678 |
|
|
2021
Q2 | $78K | Sell |
487
-1,190
| -71% | -$92.7K | ﹤0.01% | 7081 |
|
|
2021
Q1 | $134K | Buy |
+1,677
| New | +$113K | ﹤0.01% | 5339 |
|
|
2020
Q3 | – | Sell |
-25,112
| Closed | -$524K | – | 8258 |
|
|
2020
Q2 | $527K | Sell |
25,112
-3
| -0% | -$51 | ﹤0.01% | 2836 |
|
|
2020
Q1 | $307K | Buy |
+25,115
| New | +$338K | ﹤0.01% | 3135 |
|
|
2019
Q2 | – | Sell |
-18,029
| Closed | -$283K | – | 7560 |
|
|
2019
Q1 | $307K | Buy |
18,029
+14,361
| +392% | +$214K | ﹤0.01% | 3173 |
|
|
2018
Q4 | $50K | Sell |
3,668
-11,047
| -75% | -$205K | ﹤0.01% | 4527 |
|
|
2018
Q3 | $421K | Sell |
14,715
-9,324
| -39% | -$271K | ﹤0.01% | 2815 |
|
|
2018
Q2 | $657K | Buy |
24,039
+3,162
| +15% | +$76.6K | ﹤0.01% | 2190 |
|
|
2018
Q1 | $440K | Sell |
20,877
-26,841
| -56% | -$660K | 0.02% | 777 |
|
|
2017
Q4 | $917K | Buy |
47,718
+42,202
| +765% | +$974K | 0.04% | 428 |
|
|
2017
Q3 | $137K | Buy |
+5,516
| New | +$104K | 0.01% | 1469 |
|
|
2017
Q2 | – | Sell |
-5,920
| Closed | -$82.7K | – | 6570 |
|
|
2017
Q1 | $83K | Buy |
+5,920
| New | +$79.4K | ﹤0.01% | 1919 |
|
Other funds holding NTLA
AIM
RCM
RP
Simplex Trading's NTLA Position: Q2 2026 in Review
Simplex Trading opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 45,550 shares worth $771K. The stake represents ﹤0.01% of the portfolio and ranks #3076 among its holdings. This is a return to the name: Simplex Trading previously reported a position in NTLA as recently as Q3 2025.
Simplex Trading first reported a position in NTLA in Q1 2017 and has held it in 28 quarters since. The position peaked at $2.54M in Q3 2025. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Simplex Trading held 45,550 shares of Intellia Therapeutics worth $771K as of Q2 2026.
- Intellia Therapeutics was a new Simplex Trading position in Q2 2026.
- Intellia Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3076 holding.
- Simplex Trading first reported a position in Intellia Therapeutics in Q1 2017 and has held it in 28 quarters since.
- Simplex Trading's Intellia Therapeutics position peaked at $2.54M in Q3 2025.
- 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.